Payment overview · 2025
General Payments
$120,756.26
88 reported records · 21 companies
Healthcare provider profile · identity verified
Calvin Rushing, DPM
Podiatric Medicine & Surgery Service Providers|Podiatrist · SUNNYVALE, TX · NPI 1497109433
Verified facts
What the public records show
CMS Open Payments records show Calvin Rushing, DPM received $120,756.26 in general payments during 2025 across 88 reported records.
Alafair Biosciences, Inc. accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alafair Biosciences, Inc. | Unresolved — no canonical attribution shown | $33,269.96 | 27.6% | 15 | 2025 |
| Bone Support Inc. | Unresolved — no canonical attribution shown | $27,413.98 | 22.7% | 19 | 2025 |
| Fusion Orthopedics USA, LLC | Unresolved — no canonical attribution shown | $24,050.59 | 19.9% | 13 | 2025 |
| Fuse Medical, Inc. | Unresolved — no canonical attribution shown | $12,000.00 | 9.9% | 2 | 2025 |
| Voom Medical Devices, Inc. | Unresolved — no canonical attribution shown | $9,917.56 | 8.2% | 8 | 2025 |
| Linvatec Corporation | Unresolved — no canonical attribution shown | $8,893.10 | 7.4% | 9 | 2025 |
| F&A Foundation, LLC | Unresolved — no canonical attribution shown | $2,750.00 | 2.3% | 2 | 2025 |
| Trilliant Surgical LLC. | Unresolved — no canonical attribution shown | $1,625.00 | 1.4% | 1 | 2025 |
| CPM Medical Consultants, LLC | Unresolved — no canonical attribution shown | $197.50 | 0.2% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $121.94 | 0.1% | 4 | 2025 |
| TREACE MEDICAL CONCEPTS, INC. | Unresolved — no canonical attribution shown | $114.84 | 0.1% | 1 | 2025 |
| Kuros Biosciences USA, Inc | Unresolved — no canonical attribution shown | $112.50 | 0.1% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $70.76 | 0.1% | 3 | 2025 |
| Innovation Technologies Inc | Unresolved — no canonical attribution shown | $48.55 | 0.0% | 2 | 2025 |
| Arthrosurface Incorporated | Unresolved — no canonical attribution shown | $43.37 | 0.0% | 1 | 2025 |
| Heron Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.98 | 0.0% | 1 | 2025 |
| AXOGEN | Unresolved — no canonical attribution shown | $29.35 | 0.0% | 1 | 2025 |
| Davol Inc. | Unresolved — no canonical attribution shown | $25.08 | 0.0% | 1 | 2025 |
| Orthofix Medical, Inc. | Unresolved — no canonical attribution shown | $20.11 | 0.0% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $18.12 | 0.0% | 1 | 2025 |
| Electronic Waveform Lab, Inc. | Unresolved — no canonical attribution shown | $1.97 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $71,900.00 | 25 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $32,500.00 | 10 |
| Travel and Lodging | $7,459.08 | 11 |
| Charitable Contribution | $4,000.00 | 1 |
| Food and Beverage | $3,937.46 | 40 |
| Royalty or License | $959.72 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VersaWrap Normalized: versawrap |
Device | Alafair Biosciences, Inc. | $33,269.96 | 15 | 2025 |
Source payment records
|
|||||
| CERAMENT G Normalized: cerament g |
Device | Bone Support Inc. | $27,413.98 | 19 | 2025 |
Source payment records
|
|||||
| CERAMENTBONE VOID FILLER Normalized: ceramentbone void filler |
Device | Bone Support Inc. | $27,413.98 | 19 | 2025 |
Source payment records
|
|||||
| BIOBRACE 23MM Normalized: biobrace 23mm |
Device | Linvatec Corporation | $8,893.10 | 9 | 2025 |
Source payment records
|
|||||
| REVCON INSTRUMENT KIT, STERILE Normalized: revcon instrument kit sterile |
Device | Voom Medical Devices, Inc. | $5,200.00 | 4 | 2025 |
Source payment records
|
|||||
| VOOM MEDICAL REVCONTM SCREW SYSTEM Normalized: voom medical revcontm screw system |
Device | Voom Medical Devices, Inc. | $4,717.56 | 4 | 2025 |
Source payment records
|
|||||
| Arsenal Ankle Normalized: arsenal ankle |
Device | Trilliant Surgical LLC. | $1,625.00 | 1 | 2025 |
Source payment records
|
|||||
| BoloButton Normalized: bolobutton |
Device | Fusion Orthopedics USA, LLC | $959.72 | 1 | 2025 |
Source payment records
|
|||||
| Metalogix Normalized: metalogix |
Device | Fusion Orthopedics USA, LLC | $959.72 | 1 | 2025 |
Source payment records
|
|||||
| LAPIPLASTY SYSTEM 1 Normalized: lapiplasty system 1 |
Device | TREACE MEDICAL CONCEPTS, INC. | $114.84 | 1 | 2025 |
Source payment records
|
|||||
| MAGNETOS Normalized: magnetos |
Device | Kuros Biosciences USA, Inc | $112.50 | 1 | 2025 |
Source payment records
|
|||||
| Salto Talaris Total Ankle Prosthesis Normalized: salto talaris total ankle prosthesis |
Device | Smith+Nephew, Inc. | $106.00 | 3 | 2025 |
Source payment records
|
|||||
| HERCULES SUTURE ANCHOR SYSTEM Normalized: hercules suture anchor system |
Device | Linvatec Corporation | $57.49 | 1 | 2025 |
Source payment records
|
|||||
| IRRISEPT Normalized: irrisept |
Device | Innovation Technologies Inc | $48.55 | 2 | 2025 |
Source payment records
|
|||||
| TOE MOTIONTM Normalized: toe motiontm |
Device | Arthrosurface Incorporated | $43.37 | 1 | 2025 |
Source payment records
|
|||||
| DUROLANE Normalized: durolane |
Device | Bioventus LLC | $38.54 | 1 | 2025 |
Source payment records
|
|||||
| EXOGEN ULTRASOUND BONE HEALING SYSTEM Normalized: exogen ultrasound bone healing system |
Device | Bioventus LLC | $32.22 | 2 | 2025 |
Source payment records
|
|||||
| ZYNRELEF Normalized: zynrelef |
Drug | Heron Therapeutics, Inc. | $31.98 | 1 | 2025 |
Source payment records
|
|||||
| ARISTA Normalized: arista |
Device | Davol Inc. | $25.08 | 1 | 2025 |
Source payment records
|
|||||
| Physio-Stim Normalized: physio stim |
Device | Orthofix Medical, Inc. | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| AUGMENT INJECTABLE Normalized: augment injectable |
Device | Stryker Corporation | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| STRAVIX Normalized: stravix |
Biological | Smith+Nephew, Inc. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 120 | 39 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 94 | 61 |
| Celecoxib | Celecoxib | 92 | 61 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 75 | 57 |
| Mupirocin | Mupirocin | 50 | 37 |
| Pregabalin | Pregabalin | 48 | 30 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 43 | 32 |
| Methylprednisolone | Methylprednisolone | 37 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 20 |
| Meloxicam | Meloxicam | 21 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 17 |
| Tramadol Hcl | Tramadol Hcl | 20 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $120,756.26 · 88 records | Alafair Biosciences, Inc. | ARISTA, AUGMENT INJECTABLE, Arsenal Ankle, BIOBRACE 23MM, BoloButton, CERAMENT G, CERAMENTBONE VOID FILLER, DUROLANE, EXOGEN ULTRASOUND BONE HEALING SYSTEM, HERCULES SUTURE ANCHOR SYSTEM, IRRISEPT, LAPIPLASTY SYSTEM 1, MAGNETOS, Metalogix, Physio-Stim, REVCON INSTRUMENT KIT, STERILE, STRAVIX, Salto Talaris Total Ankle Prosthesis, TOE MOTIONTM, VOOM MEDICAL REVCONTM SCREW SYSTEM, VersaWrap, ZYNRELEF | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error